Vor Bio Announces Final Two-Year Results from Phase 3 TELIGAN Trial of Telitacicept in IgA Nephropathy

Vor Bio announced the final two-year results from the Phase 3 TELIGAN trial of telitacicept for IgA nephropathy, showing a significant improvement in annualized estimated glomerular filtration rate (eGFR) in treated patients, with a slope of -0.6 mL/min/1.73 m²/year compared to -5.7 mL/min/1.73 m²/year for placebo. The trial also reported an 89% reduction in the risk of confirmed ≥30% eGFR declines and an 81% reduction for ≥40% declines. These results were presented at the American Society of Nephrology Kidney Week 2026.